Used in the synthesis of glycopeptide-based vaccines and therapeutic agents, this compound enables site-specific incorporation of protected glucose-modified threonine into peptide chains via solid-phase peptide synthesis. Its Fmoc group allows for mild, base-labile deprotection compatible with sensitive glycosidic linkages, making it ideal for constructing complex glycopeptides with defined glycosylation patterns. Commonly applied in research on O-linked glycopeptides, particularly in studies related to mucin-type glycosylation and immune response modulation. Also utilized in developing synthetic antigens and probing glycosylation effects on peptide conformation and stability.